Effect of kolaviron, a biflavanoid complex from Garcinia kola on some biochemical parameters in experimentally induced benign prostatic hyperplasic rats - 21/10/16
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Background |
To determine the effect of kolaviron on some biochemical parameters in benign prostatic hyperplasia (BPH) rats.
Methods |
BPH was induced in rats using a mixture of dihydrotestosterone and estradiol valerate (10:1).
Results |
The lethal dose of kolaviron was 3050 mg/kg body weight. Body weights, relative heart weight (RHW), relative liver weight (RLW), serum levels of prostate specific antigen, prolactin, estradiol, testosterone, testosterone/estradiol ratio, aspartate transaminase (AST), alanine transaminase (ALT), urea, creatinine and prostatic levels of total proteins in the normal rats administered finasteride (standard drug) or kolaviron were not different (P > 0.05) from normal control whereas most of these parameters were altered in the disease control except RHW, RLW, AST and ALT. Finasteride (5 mg/70 kg) or kolaviron (100 and 200 mg/kg) ameliorated most of these parameters compared with disease control except RHW, RLW, prolactin, AST, ALT, urea and creatinine (for kolaviron at 100 mg/kg). The normal rats administered finasteride or kolaviron had decreased prostate weights (P < 0.05) compared with the normal control which results were corroborated by histological assay that also showed that treatment with kolaviron (200 mg/kg) or finasteride reversed the histoarchitecture of the prostates of the BPH rats.
Conclusion |
Kolaviron could be useful in the management of BPH.
Le texte complet de cet article est disponible en PDF.Keywords : Prostatic disease, Herbal medicine, Kolaviron, Hormones
Plan
Vol 83
P. 1436-1443 - octobre 2016 Retour au numéro
Article précédent
- Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment
- DongMei Yu, Wei Li, Yueying Zhang, Bin Zhang
- Ropren® treatment reverses anxiety-like behavior and monoamines levels in gonadectomized rat model of Alzheimer’s disease
- Julia Fedotova, Vagif Soultanov, Tamara Nikitina, Victor Roschin, Natalia Ordyan, Lucian Hritcu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?